Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Tailoring Treatment in Obstructive Lung Disease: Asthma, COPD, Asthma/COPD Overlap and Eosinophilic COPD
TL;DR: Both diagnosis and treatment of COPD and asthma and the recently established disease asthma/COPD overlap (ACO) and the particular challenges treating obstructive lung disease in elderly patients is more challenging than in younger patients.
Journal ArticleDOI
Biologic therapy in severe asthma: An update
TL;DR: Symptom control in the majority of asthma patients is usually achieved with the gold standard regimen, inhaled corticosteroid (ICS), however approximately 20% of patients do not achieve control, increasing mortality, morbidity and overall healthcare cost.
Journal ArticleDOI
Biologics in severe difficult-to-treat asthma: find the right niche!
TL;DR: It is very difficult to predict the efficacy of biologics in severe asthma and only one MAb directed to immunoglobulin (Ig)E was found to be effective and approved by both the US Food and Drug Administration and the European Medicines Agency for the treatment of a subset of allergicAsthma patients.
Omalizumab en las guías de tratamiento del asma
TL;DR: Omalizumab as mentioned in this paper was the primera incorporación novedosa en las guias del asma por su especificidad, dirigirse a un mecanismo concreto de la inflamacion asmatica: el bloqueo de los receptores de alta afinidad IgE en the membrana de los mastocitos, con el objetivo de evitar la liberacion de mediadores de the inflamación asmatica; esto ocurrio en 2005 and, desde
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.